echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Med: Phase I trial and biomarker analysis of Belzutifan's inhibition of renal cell carcinoma

    Nat Med: Phase I trial and biomarker analysis of Belzutifan's inhibition of renal cell carcinoma

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A better understanding of the molecular biology of renal cell carcinoma (RCC) can lead to the substantial development of treatment options.


    The VHL gene is lost in approximately 90% of ccRCC tumors.


    Blood vessel

    Hypoxia-inducible factor-2α (HIF-2α) is a transcription factor that often accumulates in clear cell renal cell carcinoma (ccRCC), resulting in the constitutive activation of genes involved in carcinogenesis.


    Belzutifan (MK-6482, formerly known as PT2977) is a potent and selective HIF-2α small molecule inhibitor.


    Efficacy outcome of the ccRCC cohort

    Efficacy outcome of the ccRCC cohort

    In the dose-escalation cohort (n = 43), no dose-limiting toxicity occurred and the maximum tolerated dose was not reached when the dose reached 160 mg once a day; RP2D was 120 mg once a day.


    A decrease in plasma erythropoietin was observed at all doses; the concentration of erythropoietin correlated with the plasma concentration of belsutifan.


    The objective response rate was 25% (all partial responses), and the median progression-free survival was 14.


    Belzutifan was well tolerated and showed preliminary antitumor activity in a large number of pretreated patients.


    Original source:

    Original source:

    Toni K.


    Toni K.


     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.